OncoHelix is the first laboratory in Canada to adopt MSK-ACCESS® powered with SOPHiA DDM™
Press releases
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2024 on August 6, 2024
BOSTON, United States and ROLLE, Switzerland, July 23, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a...
India-Based Dhiti Omics is Now Live on SOPHiA DDM™
The diagnostics company has implemented the SOPHiA DDM™ Platform to enhance its solid tumor...
SOPHiA GENETICS Publishes Results of 2024 Annual General Meeting
Shareholders adopt all proposals at Annual General Meeting Boston, US and Rolle, Switzerland, June...
SOPHiA GENETICS Launches New Residual Acute Myeloid (RAM) Application
Novel application supports measurable residual disease (MRD) testing to help monitor cancer and...
IUCT-Oncopole Becomes First French Hospital to Adopt MSK-ACCESS® powered with SOPHiA DDM™
The French comprehensive cancer center implements liquid biopsy test to further its cancer...
SOPHiA GENETICS Announces Kepler Uniklinikum is Live on SOPHiA DDM™ Platform
The Hospital will use SOPHiA DDM™ to enhance its testing and research of blood cancers Boston, MA...
SOPHiA GENETICS Launches Global Consortium, SOPHiA UNITY, to Accelerate Cancer Research, Drug Development, and Data-Driven Patient Care
New collective intelligence network to enable the most advanced research in oncology in support of...
SOPHiA GENETICS to Launch New Whole Genome Sequencing Capabilities
In collaboration with Microsoft and NVIDIA, SOPHiA GENETICS is developing a comprehensive whole...
SOPHiA GENETICS Announces Instituto Mario Penna as New Customer
The Hospital will enhance its testing and research of blood cancers with the SOPHiA DDM™...
Klinikum Klagenfurt am Wörthersee is Live with SOPHiA GENETICS
The SOPHiA DDM™ Platform will help broaden the hospital’s cancer testing and diagnostic...
SOPHiA GENETICS Reports First Quarter 2024 Results
Consistent Operational Execution; Robust New Business Momentum; Guidance Reaffirmed BOSTON, United...